⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
globenewswire.com
REGN
ixlayer Expands Access to Evidence-Based Dermatological Care Nationwide
prnewswire.com
SNY
REGN
COVID-19 Diagnostic Research Report 2025: 5 Year Forecast by Technology, Product, Channel and Country, with Executive and Consultant Guides - ResearchAndMarkets.com
businesswire.com
ABT
AMGN
BDX
BIO
CERN
DGX
DHR
ENZ
EXAS
GILD
HHC
HOLX
ILMN
ISRG
JNJ
LH
LMT
MRNA
MYL
NBIX
NOC
NTRA
NVTA
ONVO
ORCL
PDD
PFE
QGEN
QRVO
REGN
RHHBY
RMD
ROST
SGEN
SIGA
SNPS
SPLK
SRPT
STEM
SYK
TCOM
TGT
TMO
TSLA
TXG
VRTX
WBA
XRAY
Immunoassay Market Research, Strategies, Trends and Forecasts Report 2025 with Executive Guides and Impact of Artificial Intelligence - ResearchAndMarkets.com
businesswire.com
ALGN
AMZN
BDX
BIO
BMY
CDNS
CERN
CHKP
CLVS
CODX
CRSP
CYTK
DELL
DGX
DHR
DIS
DTC
DXCM
ENZ
EXAS
FSLR
GILD
GOOG
IDXX
ILMN
INCY
INTC
ISRG
JNJ
LULU
LUMX
MDLZ
MRNA
MSFT
MYL
NBIX
NCLH
NFLX
NVS
NVTA
ORCL
ORGO
OSIP
OTIS
PANW
PFE
PG
PGR
PPC
PRGO
QCOM
QGEN
QORV
QUID
REGN
ROCH
ROST
SGEN
SIRI
SNPS
SPLK
SRPT
SWKS
SYK
TCOM
TEAM
TEVA
TGT
TMO
TSLA
TXN
ULTA
UNH
VRTX
WBA
WDC
WEC
WFC
XRAY
XTRA
ZBRA
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
globenewswire.com
REGN
World COPD Day: Lung Association Offers Free Access to Lung Health Navigators to People with COPD Nationwide
prnewswire.com
SNY
REGN
AZN
GNE
GSK
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
globenewswire.com
REGN
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
globenewswire.com
REGN
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
globenewswire.com
REGN
Regeneron Announces Investor Conference Presentations
globenewswire.com
REGN